View Item 

Show simple item record

Statin withdrawal after major noncardiac surgery: Risks, consequences, and preventative strategies
dc.contributor.authorFallouh, Nabilen_US
dc.contributor.authorChopra, Vineeten_US
dc.date.accessioned2012-10-02T17:20:10Z
dc.date.available2013-10-18T17:47:30Zen_US
dc.date.issued2012-09en_US
dc.identifier.citationFallouh, Nabil; Chopra, Vineet (2012). "Statin withdrawal after major noncardiac surgery: Risks, consequences, and preventative strategies." Journal of Hospital Medicine 7(7): 573-579. <http://hdl.handle.net/2027.42/93700>en_US
dc.identifier.issn1553-5592en_US
dc.identifier.issn1553-5606en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93700
dc.description.abstractBACKGROUND: A growing body of research suggests that statins improve perioperative cardiac outcomes by attenuating inflammation. Conversely, some studies suggest that withdrawal of statins after surgery results in an upsurge of inflammation and adverse cardiac outcomes. METHODS: We performed a literature search using multiple medical databases to examine the basic, clinical, and experimental evidence supporting the existence of a statin withdrawal state. Studies examining outcomes associated with statin withdrawal were narratively synthesized. RESULTS: Published evidence suggests that statin withdrawal is associated with worse cardiac outcomes in a variety of scenarios, including acute coronary syndrome, ischemic stroke, and surgery. Although certain reasons for postoperative statin cessation are difficult to avoid (eg, ileus after surgery), we posit that many perioperative clinicians may be unaware of the importance of statin resumption in a timely fashion. This lack of awareness translates into preventable harm and an opportunity for outcome improvement. We introduce innovative practices through which perioperative practitioners may prevent statin discontinuation. CONCLUSIONS: Ensuring the resumption of statins after surgery should become routine practice for perioperative providers. We highlight knowledge gaps and identify a research agenda aimed at better understanding this practice. Journal of Hospital Medicine 2012; © 2012 Society of Hospital Medicineen_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleStatin withdrawal after major noncardiac surgery: Risks, consequences, and preventative strategiesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of General Internal Medicine, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of General Internal Medicine, University of Michigan Health System, 1500 E Medical Center Dr, SPC 5376, Ann Arbor, MI 48109en_US
dc.identifier.pmid22744758en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93700/1/1945_ftp.pdf
dc.identifier.doi10.1002/jhm.1945en_US
dc.identifier.sourceJournal of Hospital Medicineen_US
dc.identifier.citedreferenceDaskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population‐based study. Eur Heart J. 2008; 29 ( 17 ): 2083 – 2091.en_US
dc.identifier.citedreferenceSposito AC, Carvalho LS, Cintra RM, et al. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis. 2009; 207 ( 1 ): 191 – 194.en_US
dc.identifier.citedreferenceEndres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004; 35 ( 11 suppl 1 ): 2708 – 2711.en_US
dc.identifier.citedreferenceDunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE‐IV). Ann Surg. 2009; 249 ( 6 ): 921 – 926.en_US
dc.identifier.citedreferenceChopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta‐analysis. Arch Surg. 2012; 147 ( 2 ): 181 – 189.en_US
dc.identifier.citedreferenceSpencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non‐ST‐segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med. 2004; 164 ( 19 ): 2162 – 2168.en_US
dc.identifier.citedreferenceHeeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002; 105 ( 12 ): 1446 – 1452.en_US
dc.identifier.citedreferenceMcGowan MP. There is no evidence for an increase in acute coronary syndromes after short‐term abrupt discontinuation of statins in stable cardiac patients. Circulation. 2004; 110 ( 16 ): 2333 – 2335.en_US
dc.identifier.citedreferenceColivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007; 38 ( 10 ): 2652 – 2657.en_US
dc.identifier.citedreferenceBlanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007; 69 ( 9 ): 904 – 910.en_US
dc.identifier.citedreferencePrinz V, Laufs U, Gertz K, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008; 39 ( 2 ): 433 – 438.en_US
dc.identifier.citedreferenceSchouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high‐risk patients undergoing major vascular surgery. Am J Cardiol. 2005; 95 ( 5 ): 658 – 660.en_US
dc.identifier.citedreferenceLexi‐Comp Online™, Lexi‐Drugs™, Hudson, OH: Lexi‐Comp, Inc; December 7, 2011.en_US
dc.identifier.citedreferenceDexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001; 345 ( 13 ): 965 – 970.en_US
dc.identifier.citedreferenceKucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352 ( 10 ): 969 – 977.en_US
dc.identifier.citedreferenceGeurts MM, Talsma J, Brouwers JR, de Gier JJ. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. January 13, 2012. doi: 10.1111/j.1365–2125.2012.04178.x.en_US
dc.identifier.citedreferenceAmerican College of Surgeons National Surgical Quality Improvement Program. Available at: http://www.acsnsqip.org. Accessed December 15, 2012.en_US
dc.identifier.citedreferenceDurazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004; 39 ( 5 ): 967 – 975.en_US
dc.identifier.citedreferenceHindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006; 105 ( 6 ): 1260 – 1272; quiz 1289–1290.en_US
dc.identifier.citedreferenceLindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid‐lowering therapy and in‐hospital mortality following major noncardiac surgery. JAMA. 2004; 291 ( 17 ): 2092 – 2099.en_US
dc.identifier.citedreferenceO'Neil‐Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005; 45 ( 3 ): 336 – 342.en_US
dc.identifier.citedreferencePoldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003; 107 ( 14 ): 1848 – 1851.en_US
dc.identifier.citedreferenceSchouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009; 361 ( 10 ): 980 – 989.en_US
dc.identifier.citedreferenceFleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007; 116 ( 17 ): e418 – e499.en_US
dc.identifier.citedreferencePoldermans D, Bax JJ, Boersma E, et al. Guidelines for pre‐operative cardiac risk assessment and perioperative cardiac management in non‐cardiac surgery. Eur Heart J. 2009; 30 ( 22 ): 2769 – 2812.en_US
dc.identifier.citedreferenceLe Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007; 104 ( 6 ): 1326 – 1333.en_US
dc.identifier.citedreferenceSchouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007; 100 ( 2 ): 316 – 320.en_US
dc.identifier.citedreferenceDavignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109 ( 23 suppl 1 ): III39 – III43.en_US
dc.identifier.citedreferenceRoth‐Isigkeit A, Brechmann J, Dibbelt L, Sievers HH, Raasch W, Schmucker P. Persistent endocrine stress response in patients undergoing cardiac surgery. J Endocrinol Invest. 1998; 21 ( 1 ): 12 – 19.en_US
dc.identifier.citedreferenceDawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996; 57 ( 1 ): 37 – 44.en_US
dc.identifier.citedreferenceDevereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. Can Med Assoc J. 2005; 173 ( 6 ): 627 – 634.en_US
dc.identifier.citedreferenceMangano DT. Perioperative cardiac morbidity. Anesthesiology. 1990; 72 ( 1 ): 153 – 184.en_US
dc.identifier.citedreferenceLaufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003; 5 ( 5 ): 372 – 378.en_US
dc.identifier.citedreferenceLaufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97 ( 12 ): 1129 – 1135.en_US
dc.identifier.citedreferenceNoma K, Goto C, Nishioka K, et al. Roles of rho‐associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007; 49 ( 6 ): 698 – 705.en_US
dc.identifier.citedreferenceSawada N, Itoh H, Ueyama K, et al. Inhibition of rho‐associated kinase results in suppression of neointimal formation of balloon‐injured arteries. Circulation. 2000; 101 ( 17 ): 2030 – 2033.en_US
dc.identifier.citedreferenceSeljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002; 162 ( 1 ): 179 – 185.en_US
dc.identifier.citedreferenceTakemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108 ( 10 ): 1429 – 1437.en_US
dc.identifier.citedreferenceWang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008; 14 ( 1 ): 37 – 44.en_US
dc.identifier.citedreferenceWassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II‐mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59 ( 3 ): 646 – 654.en_US
dc.identifier.citedreferenceGertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003; 34 ( 2 ): 551 – 557.en_US
dc.identifier.citedreferenceLaufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000; 102 ( 25 ): 3104 – 3110.en_US
dc.identifier.citedreferenceLi JJ, Li YS, Chu JM, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta. 2006; 366 ( 1–2 ): 269 – 273.en_US
dc.identifier.citedreferencePuccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003; 90 ( 3 ): 476 – 482.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
1945_ftp.pdf
Size:
329.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.